<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28932" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Serum Sickness</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rixe</surname>
            <given-names>Nancy</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tavarez</surname>
            <given-names>Melissa M.</given-names>
          </name>
          <aff>Un of Pittsburgh School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nancy Rixe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Melissa Tavarez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28932.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Serum sickness is a rare but important cause of fever, arthritis, and rash in both children and adults. This activity reviews the differences between the pathophysiology, clinical presentation, diagnosis and management of serum sickness versus serum-sickness-like-reaction. This activity highlights the role of the interprofessional team in caring for patients affected by serum sickness.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of serum sickness and compare it to that of serum sickness-like-reaction.</p></list-item><list-item><p>Review the clinical presentation of serum sickness and serum sickness-like-reaction.</p></list-item><list-item><p>Describe the diagnostic evaluation of a patient with serum sickness.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication in the management of serum sickness.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28932&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28932">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28932.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Serum sickness is an immune-complex-mediated hypersensitivity reaction that classically presents with fever, rash, polyarthritis or polyarthralgias. It was first recognized as an entity in the early 1900s in patients who had received heterologous antisera, which was historically used to treat infectious diseases. The symptoms typically occur&#x000a0;one to two weeks after exposure to an offending agent and resolve within several weeks of discontinuation.&#x000a0;<xref ref-type="bibr" rid="article-28932.r1">[1]</xref> It is a self-limited disease process with an excellent prognosis.&#x000a0;</p>
      </sec>
      <sec id="article-28932.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The symptoms of serum sickness arise as a result of the formation of immune complexes between human proteins and heterologous (nonhuman) proteins. Medications containing heterologous antigens are the most common cause of serum sickness and include vaccinations (i.e., Rabies), immune modulating agents (i.e., rituximab, infliximab) and anti-venoms.&#x000a0;<xref ref-type="bibr" rid="article-28932.r2">[2]</xref><xref ref-type="bibr" rid="article-28932.r3">[3]</xref><xref ref-type="bibr" rid="article-28932.r4">[4]</xref>&#x000a0;</p>
        <p>Serum sickness is not to be confused with a serum sickness-like reaction, which results in a similar clinical presentation but does not involve the formation of immune complexes. The most common&#x000a0;offending medications include&#x000a0;penicillins, cephalosporins (most commonly cefaclor), sulfonamides, bupropion, fluoxetine, and thiouracil.&#x000a0;<xref ref-type="bibr" rid="article-28932.r5">[5]</xref><xref ref-type="bibr" rid="article-28932.r6">[6]</xref> Also, several infections can lead to the development of serum sickness-like reaction, including streptococcus and hepatitis B.&#x000a0;<xref ref-type="bibr" rid="article-28932.r7">[7]</xref><xref ref-type="bibr" rid="article-28932.r8">[8]</xref></p>
      </sec>
      <sec id="article-28932.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Although considered a rare overall entity, serum sickness is more common in adults than in children. One study of 72,000 patients found that serum sickness was found in less than 0.5 percent of children under ten years who received human and equine anti-rabies globulins.&#x000a0;<xref ref-type="bibr" rid="article-28932.r9">[9]</xref>&#x000a0;Certain patient populations are considered to be at a higher risk for developing serum sickness following rituximab infusion, including those with hypergammaglobulinemia and Hepatitis C-related cryoglobulinemia vasculitis.&#x000a0;<xref ref-type="bibr" rid="article-28932.r10">[10]</xref><xref ref-type="bibr" rid="article-28932.r11">[11]</xref></p>
      </sec>
      <sec id="article-28932.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>When a patient is exposed to a foreign serum protein, it takes approximately 6-10 days for antibodies to develop and form antigen-antibody complexes and&#x000a0;is considered a Type III immune-mediated hypersensitivity reaction. <xref ref-type="bibr" rid="article-28932.r1">[1]</xref>&#x000a0;If the macrophage activating system is not functioning properly, these complexes will become saturated in the circulation, leading to immune complex deposition, most commonly in parenchymal tissues and synovial joint fluid. The deposition of immune complexes may also activate the classical complement pathway, leading to lower levels of circulating C3 and C4. These levels can be used to differentiate serum sickness from a serum sickness-like reaction, which will have normal complement levels. <xref ref-type="bibr" rid="article-28932.r1">[1]</xref>&#x000a0;Also, the activation of the complement system will trigger histamine release and increase vascular permeability, which&#x000a0;leads to an inflammatory response in the tissues and joints. It is the process of clearing these immune complexes and the subsequent inflammatory reaction that&#x000a0;coincides with the onset of clinical symptoms. <xref ref-type="bibr" rid="article-28932.r12">[12]</xref>&#x000a0;Note that in patients previously sensitized to the antigen, symptoms may develop within a few days of re-exposure to the causative agent.</p>
      </sec>
      <sec id="article-28932.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical exam are essential in the evaluation of suspected serum sickness. The history should focus on identification of an offending agent within the two weeks before the onset of symptoms, or, in the case of potential repeat exposure, within the few days before presentation. Also, a complete review of systems, with a focus on each organ system and severity of symptoms, should be performed to evaluate for other&#x000a0;potential causes of the patient's&#x000a0;presentation.</p>
        <p>The physical exam should be carefully undertaken to determine the severity of symptoms and signs of systemic illness.&#x000a0;A close inspection of the rash may reveal an urticarial, maculopapular or vasculitic (purpuric) eruption. Importantly, the mucous membranes are not involved and can be helpful in distinguishing serum sickness from Stevens-Johnson syndrome or toxic epidermal necrolysis. If associated with subcutaneous injection, the rash may first appear around the site of the injection. The rash typically takes days to weeks to resolve once the offending agent is discontinued. Arthralgias are more common than frank arthritis, but&#x000a0;either may occur. The hands, feet, ankles, knees, and shoulders are most commonly affected. Less common findings on the physical exam include edema (i.e., of the hands, feet, and face), lymphadenopathy, headache or blurry vision, splenomegaly, anterior uveitis, peripheral neuropathy, nephropathy, and vasculitis.&#x000a0;<xref ref-type="bibr" rid="article-28932.r13">[13]</xref>&#x000a0;Of note, these systemic symptoms are less likely in serum sickness-like reaction, which is usually limited to fever, arthralgias, rash/urticaria, and pruritis.</p>
      </sec>
      <sec id="article-28932.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation of well-appearing patients with suspected serum sickness can be limited to urinalysis to determine the presence of renal involvement, which would require close follow-up. However, if the patient is ill-appearing or if there is any degree of diagnostic uncertainty based on the history or physical exam, further testing should be performed. The clinician should consider the following laboratory tests to evaluate for other etiologies and multi-organ system involvement: complete blood count with differential, erythrocyte sedimentation rate, C-reactive protein, total hemolytic complement (CH50), C3, C4, basic metabolic panel, liver transaminases, antinuclear antibody, and rheumatoid factor. <xref ref-type="bibr" rid="article-28932.r12">[12]</xref>&#x000a0;Depending on the clinical history, testing for infectious diseases may include&#x000a0;hepatitis B screen and heterophile antibody testing for EBV. If carditis is suspected, an electrocardiogram should be obtained. Stool hematocrit should be obtained in any patient with gastrointestinal symptoms.&#x000a0;Neuroimaging with a computed tomography scan&#x000a0;should be considered in patients with neurological complaints.</p>
        <p>Laboratory results in serum sickness may be widely variable. The complete blood count can show leukopenia or mild leukocytosis. Serum creatinine may be elevated, but typically returns to baseline within days-weeks of discontinuing the offending agent. Inflammatory markers will be elevated in serum sickness. Complement levels including CH50, C3, and C4, will be decreased, reflecting activation and consumption of complement.&#x000a0;</p>
        <p>Recall that patients with serum sickness-like reaction will generally not manifest with additional multi-organ system symptoms as outlined above. Also, the lab&#x000a0;results in a serum sickness-like reaction will not show hypocomplementemia or renal dysfunction.&#x000a0;<xref ref-type="bibr" rid="article-28932.r14">[14]</xref></p>
      </sec>
      <sec id="article-28932.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Serum sickness is a self-limited entity that will usually resolve upon discontinuation of the offending agent, with or without additional treatment. Thus, treatment is generally aimed at reducing symptom severity and removing the agent, or reducing exposure to it if complete removal is not possible (for example, potentially life-saving anti-thymocyte globulin in the treatment of aplastic anemia). <xref ref-type="bibr" rid="article-28932.r15">[15]</xref>&#x000a0;For mild or moderate presentations, symptomatic relief can be achieved with NSAIDs and/or antihistamines. The patient should be counseled that the rash and pruritis should stop progressing within 48 hours of initiation of these medications. For more severe symptoms, a 7 to 10-day course of 0.5 - 2 mg/kg of systemic glucocorticoids can be helpful.&#x000a0;<xref ref-type="bibr" rid="article-28932.r6">[6]</xref>&#x000a0;Most children can be safely treated as outpatients, but inpatient hospitalization should be considered for those with severe symptoms, multi-organ system involvement or evidence of an underlying infection or more serious etiology.</p>
      </sec>
      <sec id="article-28932.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of serum sickness and serum sickness-like reaction is broad and requires a thorough&#x000a0;evaluation to&#x000a0;narrow the lens of focus. In general, the differential should include viral illnesses with exanthems (i.e. Chikungunya, Dengue fever), acute rheumatic fever, Scarlet fever, Kawasaki disease, meningococcemia, systemic juvenile idiopathic arthritis, Lyme disease, hypersensitivity vasculitis (i.e. IgA vasculitis, Sweet syndrome, Stevens-Johnson syndrome) and other types of drug reactions (i.e.&#x000a0;drug reaction with eosinophilia and systemic symptoms, or DRESS). Specific disease characteristics and laboratory evaluation can help to distinguish between these entities.&#x000a0;</p>
      </sec>
      <sec id="article-28932.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of serum sickness and serum sickness-like reaction is excellent. Patients generally experience resolution of symptoms within 1-2 weeks following discontinuation of the offending agent. Those with severe symptoms,&#x000a0;recurrent serum sickness, or ongoing exposure to the&#x000a0;causative agent may experience a prolonged course of illness.&#x000a0;</p>
      </sec>
      <sec id="article-28932.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Generally, serum sickness resolves on its own and does not lead to any&#x000a0;long-term complications. To date, there have been no large-scale studies demonstrating any&#x000a0;long-standing consequences of serum sickness. However, repeat exposure to a causative agent leading to multiple episodes of serum sickness has caused renal failure and death in animal models.&#x000a0;<xref ref-type="bibr" rid="article-28932.r16">[16]</xref>&#x000a0;However, studies of patients receiving anti-thymocyte globulin in the treatment of aplastic anemia, who developed serum sickness, have demonstrated more favorable outcomes.&#x000a0;<xref ref-type="bibr" rid="article-28932.r13">[13]</xref></p>
      </sec>
      <sec id="article-28932.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Following an episode of serum sickness or serum sickness-like reaction, patients should be counseled to avoid the offending agent indefinitely. The patient should be educated on the&#x000a0;generic and brand names of the medication to ensure proper avoidance. Patients should understand that, after a single episode of serum sickness, re-exposure to the same agent can result in a more severe course of illness.&#x000a0;It is currently unclear whether or not patients&#x000a0;can safely be medicated with agents of the same class following an episode of serum sickness, but some experts argue that structurally-related medications should be avoided.&#x000a0;<xref ref-type="bibr" rid="article-28932.r17">[17]</xref></p>
      </sec>
      <sec id="article-28932.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Serum sickness is a self-limited disease process that is generally alleviated&#x000a0;by the discontinuation of the offending agent. However, the differential diagnosis of serum sickness includes potentially life-threatening disease entities that need to be considered and excluded. It is the responsibility of the entire treatment team, including the physician or advanced practice provider, nurses and pharmacists, to ensure that the correct diagnosis is identified and the offending medication is discontinued indefinitely. Adjunctive therapies including NSAIDs, antihistamines, and corticosteroids may help alleviate symptom severity. For those patients in whom discontinuation of the causative agent is not possible, an interprofessional care team including, but not limited to, specialty trained nurses, assisting an allergist/immunologist, rheumatologist, and oncologist, is essential in the management of ongoing treatment and mitigation of side effects.&#x000a0;<xref ref-type="bibr" rid="article-28932.r12">[12]</xref>&#x000a0;(Level V)</p>
      </sec>
      <sec id="article-28932.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28932&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28932">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/serum-sickness/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28932">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28932/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28932">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28932.s15">
        <title>References</title>
        <ref id="article-28932.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawley</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bielory</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gascon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>A prospective clinical and immunologic analysis of patients with serum sickness.</article-title>
            <source>N Engl J Med</source>
            <year>1984</year>
            <month>Nov</month>
            <day>29</day>
            <volume>311</volume>
            <issue>22</issue>
            <fpage>1407</fpage>
            <page-range>1407-13</page-range>
            <pub-id pub-id-type="pmid">6387492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanauer</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Bala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rutgeerts</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>7</issue>
            <fpage>542</fpage>
            <page-range>542-53</page-range>
            <pub-id pub-id-type="pmid">15224278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermeire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Assche</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rutgeerts</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Serum sickness, encephalitis and other complications of anti-cytokine therapy.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2009</year>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-12</page-range>
            <pub-id pub-id-type="pmid">19258190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaeffer</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reifler</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis.</article-title>
            <source>Acad Emerg Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-31</page-range>
            <pub-id pub-id-type="pmid">22320362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misirlioglu</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozmen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bostanci</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Serum sickness-like reaction in children due to cefditoren.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2012</year>
            <season>May-Jun</season>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-8</page-range>
            <pub-id pub-id-type="pmid">22010630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clark</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kotti</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Conger</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Severe serum sickness reaction to oral and intramuscular penicillin.</article-title>
            <source>Pharmacotherapy</source>
            <year>2006</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>705</fpage>
            <page-range>705-8</page-range>
            <pub-id pub-id-type="pmid">16718943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mallette</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Studies of urticaria and acute serum sickness with the C1q precipitin test.</article-title>
            <source>Arch Intern Med</source>
            <year>1977</year>
            <month>Apr</month>
            <volume>137</volume>
            <issue>4</issue>
            <fpage>440</fpage>
            <page-range>440-2</page-range>
            <pub-id pub-id-type="pmid">139855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arkachaisri</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Serum sickness and hepatitis B vaccine including review of the literature.</article-title>
            <source>J Med Assoc Thai</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>85 Suppl 2</volume>
            <fpage>S607</fpage>
            <page-range>S607-12</page-range>
            <pub-id pub-id-type="pmid">12403239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suwansrinon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jaijareonsup</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Benjavongkulchai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sriaroon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sitprija</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Sex- and age-related differences in rabies immunoglobulin hypersensitivity.</article-title>
            <source>Trans R Soc Trop Med Hyg</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>101</volume>
            <issue>2</issue>
            <fpage>206</fpage>
            <page-range>206-8</page-range>
            <pub-id pub-id-type="pmid">16806332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scheinberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-5</page-range>
            <pub-id pub-id-type="pmid">17414540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e8;ne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ghillani-Dalbin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amoura</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Musset</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>3848</fpage>
            <page-range>3848-55</page-range>
            <pub-id pub-id-type="pmid">19950292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <collab>Joint Task Force on Practice Parameters</collab>
            <collab>American Academy of Allergy, Asthma and Immunology</collab>
            <collab>American College of Allergy, Asthma and Immunology</collab>
            <collab>Joint Council of Allergy, Asthma and Immunology</collab>
            <article-title>Drug allergy: an updated practice parameter.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>105</volume>
            <issue>4</issue>
            <fpage>259</fpage>
            <page-range>259-273</page-range>
            <pub-id pub-id-type="pmid">20934625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bielory</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gascon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lawley</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-57</page-range>
            <pub-id pub-id-type="pmid">3257288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions.</article-title>
            <source>Eur J Pediatr</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>172</volume>
            <issue>4</issue>
            <fpage>537</fpage>
            <page-range>537-43</page-range>
            <pub-id pub-id-type="pmid">23296953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bayraktar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akinci</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Demirkan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yener</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yesil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kirmaz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Comlekci</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Serum sickness-like reactions associated with type III insulin allergy responding to plasmapheresis.</article-title>
            <source>Diabet Med</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>659</fpage>
            <page-range>659-60</page-range>
            <pub-id pub-id-type="pmid">19538244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Quantitation of acute and chronic serum sickness in the rabbit.</article-title>
            <source>J Exp Med</source>
            <year>1971</year>
            <month>Sep</month>
            <day>01</day>
            <volume>134</volume>
            <issue>3 Pt 2</issue>
            <fpage>7s</fpage>
            <page-range>7s-8s</page-range>
            <pub-id pub-id-type="pmid">5570757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28932.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vial</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pont</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rabilloud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Descotes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cefaclor-associated serum sickness-like disease: eight cases and review of the literature.</article-title>
            <source>Ann Pharmacother</source>
            <year>1992</year>
            <season>Jul-Aug</season>
            <volume>26</volume>
            <issue>7-8</issue>
            <fpage>910</fpage>
            <page-range>910-4</page-range>
            <pub-id pub-id-type="pmid">1504397</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
